4,441 Shares of Revolution Medicines, Inc. $RVMD Purchased by Englebert Financial Advisers LLC

Englebert Financial Advisers LLC purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the third quarter, HoldingsChannel.com reports. The firm purchased 4,441 shares of the company’s stock, valued at approximately $912,000. Revolution Medicines makes up approximately 0.9% of Englebert Financial Advisers LLC’s holdings, making the stock its 26th largest holding.

Several other institutional investors have also recently made changes to their positions in RVMD. Burkett Financial Services LLC purchased a new position in shares of Revolution Medicines during the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. bought a new stake in Revolution Medicines during the 2nd quarter worth approximately $32,000. ABS Investment Management LLC bought a new stake in Revolution Medicines during the 2nd quarter worth approximately $337,104,000. Johnson Financial Group Inc. purchased a new position in Revolution Medicines during the second quarter valued at approximately $37,000. Finally, Mather Group LLC. purchased a new stake in shares of Revolution Medicines in the third quarter worth $41,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Price Performance

RVMD stock opened at $196.55 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The company’s fifty day moving average price is $202.54 and its 200-day moving average price is $175.28. Revolution Medicines, Inc. has a one year low of $52.48 and a one year high of $224.31. The company has a market capitalization of $42.13 billion, a PE ratio of -22.28 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the firm earned ($1.31) EPS. On average, equities analysts anticipate that Revolution Medicines, Inc. will post -8.93 EPS for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, Director Lorence H. Kim sold 56,000 shares of Revolution Medicines stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $203.24, for a total value of $11,381,440.00. Following the sale, the director directly owned 17,090 shares of the company’s stock, valued at approximately $3,473,371.60. The trade was a 76.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Alan B. Sandler sold 6,309 shares of Revolution Medicines stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total value of $1,275,301.26. Following the completion of the sale, the insider directly owned 52,559 shares in the company, valued at $10,624,276.26. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 290,991 shares of company stock worth $59,422,765. Insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on RVMD shares. TD Cowen restated a “buy” rating on shares of Revolution Medicines in a research note on Thursday, October 8th. William Blair began coverage on Revolution Medicines in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Stifel Nicolaus raised their price target on Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Brookline Capital Markets started coverage on Revolution Medicines in a research report on Monday, September 28th. They issued a “buy” rating and a $318.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $242.60.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.